The effect of a prostaglandin E1 derivative on the symptoms and quality of life of patients with lumbar spinal stenosis

Takahashi, J.; Kobayashi, Hitome; Wakabayashi, Shigeo; Deguchi, Masashi; Ito, Hidehiro; Mogami, Yuji; Tanikawa, Hirotaka; Nakagawa, Hiroyuki; Moriya, Hideki; Ashizawa, Ryohei; Takahara, Kenji; Kinoshita, Hisatoshi; Tateiwa, Yutaka; Misawa, Hiromichi; Tsutsumimoto, Takahiro; Nakakohji, Taku; Sawaumi, Akihito; Hidai, Yohei; Matsuda, Satoshi; Nakamura, Isao; Toba, Shigeyuki; Kamimura, Mikio; Nakane, Takeshi; Hirabayashi, Hiroki; Hashidate, Hiroyuki; Ogihara, Nobuhide; Mukaiyama, Keijiro; Kato, Hiroyuki; Ohtsuka, Kuniyoshi

doi:10.1007/s00776-012-0342-5

Cited by 18 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the subgroup analysis stratified by symptom severity, limaprost seemed more effective for milder symptoms. Other studies also report more favorable results using limaprost compared with NSAIDs . Furthermore, Onda et al .…”

Section: Clinical Outcomes Of Pge1 Treatment For Lscsmentioning

confidence: 89%

“…Table shows a summary of previous studies that reported clinical outcomes following the administration of limaprost for the treatment of LSCS . These include 2 randomized, double‐blind dose–response studies, 2 randomized comparative effectiveness studies, and 2 poor‐quality randomized comparative effectiveness studies.…”

Section: Clinical Outcomes Of Pge1 Treatment For Lscsmentioning

confidence: 99%

See 1 more Smart Citation

Prostaglandin E₁ Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature

Yoshihara

2015

Pain Practice

View full text Add to dashboard Cite

show abstract

Section: Clinical Outcomes Of Pge1 Treatment For Lscsmentioning

confidence: 89%

Section: Clinical Outcomes Of Pge1 Treatment For Lscsmentioning

confidence: 99%

Prostaglandin E₁ Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature

Yoshihara

2015

Pain Practice

View full text Add to dashboard Cite

show abstract

“…The results showed that the baseline-adjusted EQ-5D scores improved significantly over time in all three groups after treatment. Takahashi et al (2013) performed a survey to assess the relationships between the QoL and the therapy with limaprost or etodolac (an NSAID). The mean EQ-5D utility value for patients was 0.59 ± 0.12, which is much lower than the reported utility for patients with type 2 diabetes and stroke (0.86 and 0.84, respectively), suggesting that patients with LSS had poorer QoL.…”

Section: Discussionmentioning

confidence: 99%

Clinical Effectiveness of Conservative Treatments on Lumbar Spinal Stenosis: A Network Meta-Analysis

Chen

Zheng²,

Lin

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: To systematically evaluate the clinical effectiveness of conservative treatments including pharmacological treatments and nonpharmacological treatments on patients with lumbar spinal stenosis.Methods: We searched six electronic databases systematically for randomized clinical trials published between January 2000 and July 2021, including the China National Knowledge Infrastructure, WanFang Data, PubMed, MEDLINE, Embase, and the Cochrane library. The studies focused on the therapeutic effects of pharmacological treatments including calcitonin, antiepileptics, neurotrophic drugs, nonsteroidal anti-inflammatory drugs, Chinese Traditional Medicine, limaprost, and nonpharmacological treatments like physiotherapy for treating lumbar spinal stenosis were included. The outcome was measured using the visual analog scale, Oswestry Dysfunction Index, Japanese Orthopaedic Association Score, and EuroQol Five Dimensions Questionnaire. The quality of eligible studies was assessed by using the Cochrane recommended bias risk assessment tool. Stata was used to conduct the network meta-analysis.Results: A total of 12 randomized control trials with 1,194 patients were included. The network meta-analysis showed that for the visual analog scale, a better therapeutic effect was noted while using Chinese Traditional Medicine and physiotherapy, followed by analgesics drugs and limaprost. Limaprost and calcitonin were better in decreasing the Oswestry Dysfunction Index. In terms of the Japanese Orthopaedic Association Score, the use of traditional Chinese Medicine and limaprost were associated with a better improvement than other treatments. Meanwhile, limaprost combined with analgesics drugs was found to be effective to improve the EuroQol Five Dimensions Questionnaire.Conclusion: Among the commonly used conservative treatments for the treatment of lumbar spinal stenosis, limaprost may have better efficacy in improving the Japanese Orthopaedic Association Score and decreasing the Oswestry Dysfunction Index, with a beneficial effect on decreasing the visual analog scale and improving the EuroQol Five Dimensions Questionnaire.Systematic Review Registration: website, identifier registration number.

show abstract

“…Its mechanism of action has been thought to largely involve its property to increase peripheral blood flow by expanding blood vessels. Interestingly, limaprost has also been reported to relieve LBP [ 57 , 58 ]. It was suggested that limaprost may relieve LBP, in part by suppressing the phosphorylation of MAPKs and NGF expression by inducing DUSP-1.…”

Section: Discussionmentioning

confidence: 99%

DUSP-1 Induced by PGE2 and PGE1 Attenuates IL-1β-Activated MAPK Signaling, Leading to Suppression of NGF Expression in Human Intervertebral Disc Cells

Kusakabe

Sawaji

Endo

et al. 2021

IJMS

View full text Add to dashboard Cite

The molecular mechanism of discogenic low back pain (LBP) involves nonphysiological nerve invasion into a degenerated intervertebral disc (IVD), induced by nerve growth factor (NGF). Selective cyclooxygenase (COX)-2 inhibitors are mainly used in the treatment of LBP, and act by suppressing the inflammatory mediator prostaglandin E2 (PGE2), which is induced by inflammatory stimuli, such as interleukin-1β (IL-1β). However, in our previous in vitro study using cultured human IVD cells, we demonstrated that the induction of NGF by IL-1β is augmented by a selective COX-2 inhibitor, and that PGE2 and PGE1 suppress NGF expression. Therefore, in this study, to elucidate the mechanism of NGF suppression by PGE2 and PGE1, we focused on mitogen-activated protein kinases (MAPKs) and its phosphatase, dual-specificity phosphatase (DUSP)-1. IL-1β-induced NGF expression was altered in human IVD cells by MAPK pathway inhibitors. PGE2 and PGE1 enhanced IL-1β-induced DUSP-1 expression, and suppressed the phosphorylation of MAPKs in human IVD cells. In DUSP-1 knockdown cells established using small interfering RNA, IL-1β-induced phosphorylation of MAPKs was enhanced and prolonged, and NGF expression was significantly enhanced. These results suggest that PGE2 and PGE1 suppress IL-1β-induced NGF expression by suppression of the MAPK signaling pathway, accompanied by increased DUSP-1 expression.

show abstract

The effect of a prostaglandin E1 derivative on the symptoms and quality of life of patients with lumbar spinal stenosis

Abstract: Background. Quality of life (QOL) is a concern in patients with lumbar spinal stenosis (LSS).

Cited by 18 publications

References 17 publications

Prostaglandin E₁ Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature

Prostaglandin E₁ Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature

Clinical Effectiveness of Conservative Treatments on Lumbar Spinal Stenosis: A Network Meta-Analysis

DUSP-1 Induced by PGE2 and PGE1 Attenuates IL-1β-Activated MAPK Signaling, Leading to Suppression of NGF Expression in Human Intervertebral Disc Cells

Contact Info

Product

Resources

About

The effect of a prostaglandin E1 derivative on the symptoms and quality of life of patients with lumbar spinal stenosis

Abstract: Background. Quality of life (QOL) is a concern in patients with lumbar spinal stenosis (LSS).

Cited by 18 publications

References 17 publications

Prostaglandin E1 Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature

Prostaglandin E1 Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature

Clinical Effectiveness of Conservative Treatments on Lumbar Spinal Stenosis: A Network Meta-Analysis

DUSP-1 Induced by PGE2 and PGE1 Attenuates IL-1β-Activated MAPK Signaling, Leading to Suppression of NGF Expression in Human Intervertebral Disc Cells

Contact Info

Product

Resources

About

Prostaglandin E₁ Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature

Prostaglandin E₁ Treatment for Lumbar Spinal Canal Stenosis: Review of the Literature